Jaydess (Levonorgestrel)

Jaydess, a levonorgestrel‑releasing intrauterine system, is used within the hormonal contraceptive pathway for the following clinical indications:

• Contraception: provides highly effective, long‑term prevention of pregnancy for up to three years.
• Heavy menstrual bleeding: reduces menstrual blood loss and can improve anemia in women with dysfunctional uterine bleeding (off‑label in some regions).

• Levonorgestrel released from the intrauterine system acts locally on the endometrium and cervical mucus. The steady low‑dose release (~20 µg/day) suppresses ovulation in some cycles, thickens cervical mucus to impede sperm penetration, and induces endometrial atrophy, creating an environment unsuitable for implantation while minimizing systemic hormone exposure.

Levonorgestrel IUS may be associated with a range of adverse reactions, most of which are mild and resolve spontaneously.

Common Side Effects

• Irregular bleeding: spotting or breakthrough bleeding during the first months.
• Amenorrhea: absence of menstrual periods after initial adjustment.
• Pelvic pain or cramping: mild discomfort around the uterus.

Serious or Rare Side Effects

• Uterine perforation: possible during insertion, may need surgical management.
• Expulsion: device may be partially or fully expelled, requiring re‑insertion.
• Infection: pelvic inflammatory disease or endometritis associated with the procedure.

Before prescribing Jaydess, clinicians should consider several safety measures.

• Patient selection: confirm no current pregnancy and assess uterine size and shape.
• Contraindications: avoid in women with active pelvic infection, unexplained vaginal bleeding, or known hypersensitivity to levonorgestrel.
• Insertion timing: place within 5 days of menstrual onset or after confirmed negative pregnancy test.
• Follow‑up: schedule pelvic exam 4–6 weeks post‑insertion to verify placement.
• Device removal: plan removal after approved duration (up to 3 years) or earlier if complications arise.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and direct sunlight.

Levonorgestrel IUS may interact with other medicines that affect hormone metabolism.

Major Interactions (Avoid)

• CYP3A4 inducers: drugs such as rifampicin, carbamazepine, or phenytoin may reduce levonorgestrel effectiveness.
• Strong CYP3A4 inhibitors: agents like ketoconazole can increase systemic exposure, though clinical relevance is low for intrauterine delivery.

Moderate Interactions (Monitor Closely)

• Antiretroviral therapy: certain protease inhibitors may alter hormone levels; monitor for breakthrough bleeding.
• Herbal supplements: St. John’s wort may decrease efficacy; advise patients to discuss use.
• Prolonged broad‑spectrum antibiotics: generally safe, but review if therapy exceeds several weeks.